Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ICOS-CORE Whitepaper Calls for Rigorous Evidence to Support Cardio-oncology Rehabilitation
Added: 8 months ago Source:  Radcliffe Cardiology
A new whitepaper from the International Cardio-Oncology Society (ICOS) CORE working group outlines a critical roadmap for advancing the cardiovascular care of cancer survivors. Published in the European Heart Journal, the paper reviews the current evidence for cardio-oncology rehabilitation and exercise (CORE) programmes and sets new standards for future research to address significant knowledge… View more

Prevention & Chronic Conditions

CV Disease in Special Populations
AVR and ATTR Therapy Improve Survival in Dual Pathology
Added: 4 months ago Source:  Radcliffe Cardiology
New findings from a large, international registry suggest that in patients with the dual pathology of aortic stenosis and transthyretin-associated cardiac amyloidosis, a combination of aortic valve replacement and disease-specific medication offers the most significant survival benefit.¹ The study (NCT06129331) aimed to clarify the prognostic impact of these treatments in this increasingly… View more

Imaging & Diagnostics

Intervention
Beta-Blockers Cut MACE Risk Post-MI in Normal EF Patients
Added: 4 months ago Source:  Radcliffe Cardiology
The role of long-term beta-blocker therapy following a myocardial infarction (MI) in patients without heart failure remains a subject of clinical debate, particularly in the modern era of reperfusion and secondary prevention. The BETAMI–DANBLOCK trial sought to address this evidence gap by evaluating the efficacy of beta-blockers in this specific patient population.¹BETAMI–DANBLOCK was an open… View more

MI/ACS

Prevention & Chronic Conditions
Beta-Blockers Post-MI Show No Benefit in Preserved LVEF
Added: 1 month ago Source:  Radcliffe Cardiology
The routine use of beta-blockers following myocardial infarction (MI) in patients with a preserved ejection fraction has been a topic of clinical uncertainty. A new large-scale, individual-patient data meta-analysis from the Beta-Blocker Trialists’ Collaboration Study Group, combining five major trials, has found no significant benefit for this patient population.¹MethodologyThis meta-analysis… View more

MI/ACS

Heart Failure
Vericiguat May Reduce Total Worsening HF Events
Added: 3 months ago Source:  Radcliffe Cardiology
An exploratory analysis of the VICTOR trial suggests that in compensated patients with heart failure and reduced ejection fraction (HFrEF), vericiguat may reduce the overall burden of worsening heart failure (HF) when outpatient events are included alongside hospitalisations.¹Vericiguat is an oral soluble guanylate cyclase stimulator that enhances the cyclic guanosine monophosphate pathway,… View more

Prevention & Chronic Conditions

Heart Failure
RELAXIN-LA Trial: Volenrelaxin Linked to Worsening Congestion in HFpEF
Added: 7 months ago Source:  Radcliffe Cardiology
Treatment with volenrelaxin, a long-acting human relaxin analogue, was associated with worsening congestion in patients with recently decompensated heart failure with preserved ejection fraction (HFpEF), leading to the early termination of the phase 2 RELAXIN-LA trial.¹ Despite this, the lowest dose of the drug did show an improvement in the study's primary endpoint.Relaxin is a peptide hormone… View more

Imaging & Diagnostics

Cardiovascular Renal Metabolic
ESPRIT: Intensive BP Control Benefits Frail Patients
Added: 3 months ago Source:  Radcliffe Cardiology
Intensive blood pressure (BP) control is beneficial for high-risk hypertensive patients, regardless of their frailty status, according to a new post hoc analysis of the ESPRIT trial.¹ The findings suggest that even severely frail patients can safely achieve cardiovascular benefits from a lower systolic BP target.MethodologyThis analysis was conducted on data from the ESPRIT (Effects of intensive… View more

Demographic

Heart Failure
OPTION-STEMI: Staged Revascularisation for STEMI with HF
Added: 2 weeks ago Source:  Cardiac Failure Review
The optimal timing for complete revascularisation in patients with ST-segment elevation myocardial infarction (STEMI) and multi-vessel disease who also present with heart failure is a key clinical question. A pre-specified subgroup analysis of the OPTION-STEMI trial suggests that a staged approach may be preferable to immediate complete revascularisation in this high-risk patient group… View more

Intervention

MI/ACS
REBOOT-CNIC: Beta-Blockers Show No Benefit Post-MI in Patients with Preserved Ejection Fraction
Added: 7 months ago Source:  Radcliffe Cardiology
The long-standing practice of prescribing beta-blockers after a myocardial infarction (MI) has been re-examined in the contemporary era of reperfusion therapy. New findings from the REBOOT-CNIC trial suggest that for patients with a preserved left ventricular ejection fraction (LVEF), this routine therapy may not provide the expected benefits.¹REBOOT-CNIC was an open-label, randomised trial… View more

Imaging & Diagnostics

MI/ACS
POTCAST: Raising Potassium Levels Reduces Arrhythmia Risk in ICD Patients
Added: 6 months ago Source:  Arrhythmia Academy
A strategy of actively increasing plasma potassium to high-normal levels significantly lowered the risk of arrhythmia events in high-risk patients with an implantable cardioverter–defibrillator (ICD), according to results from the POTCAST trial.¹˒² The findings were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the New England Journal of… View more

Electrophysiology & Arrhythmia

Heart Failure